Launch of Tramal® OD Tablet 25 mg and 50 mg for the treatment of cancer pain and chronic pain.
Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa; “Nippon Shinyaku”) and Pfizer Japan Inc. (Headquarters: Tokyo, Japan; President: Ichiro Umeda; “Pfizer”) announced that the two companies have launched “Tramal® oral disintegrating (OD) Tablet 25 mg and 50 mg” on December 1, 2014. The OD Tablet has been developed by Nippon Shinyaku as an additional dosage form of “Tramal® Capsule” for the treatment of the same indication, cancer pain and chronic pain.
Its active pharmaceutical ingredient, tramadol hydrochloride, is a centrally acting analgesic licensed in from Grünenthal GmbH in Germany and launched in more than one hundred countries. As a non-scheduled medicine in Japan, tramadol is prescribed for the treatment of cancer pain and chronic pain for the many patients for whom non-opioid analgesics are not adequate.
Because Tramal® OD Tablet is disintegrated and able to take easily without water, it is useful for patients with water restrictions, impaired swallowing function, and elderly persons. It can support various needs of many patients. By adding Tramal® OD Tablet in our products line-up, both companies would like to contribute to the improvement of QOL in patients suffering from pain.
Pfizer Japan will conduct its sales promotion exclusively in Japan, while Nippon Shinyaku will market and distribute the product, as with “Tramal® Capsule 25 mg and 50 mg”.